Somewhat Negative Press Coverage Somewhat Unlikely to Impact Novan (NOVN) Share Price
Media coverage about Novan (NASDAQ:NOVN) has trended somewhat negative on Thursday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Novan earned a news impact score of -0.02 on Accern’s scale. Accern also assigned media stories about the company an impact score of 42.7981101857506 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news articles that may have effected Accern’s analysis:
- DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline – January 2, 2018 (finance.yahoo.com)
- Novan (NOVN) Stock Rating Upgraded by ValuEngine (americanbankingnews.com)
- NOVAN 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit … (businesswire.com)
- NOVN Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Novan, Inc. Investors (4-traders.com)
A number of research firms recently issued reports on NOVN. ValuEngine raised Novan from a “strong sell” rating to a “sell” rating in a research report on Friday, September 15th. Zacks Investment Research raised Novan from a “sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Finally, Wedbush reaffirmed a “neutral” rating and issued a $6.00 target price on shares of Novan in a research report on Monday, September 25th.
Shares of Novan (NASDAQ:NOVN) traded down $0.04 during midday trading on Thursday, reaching $4.30. The company’s stock had a trading volume of 61,300 shares, compared to its average volume of 51,650. The firm has a market capitalization of $69.40, a P/E ratio of -0.54 and a beta of 5.15. Novan has a 1 year low of $3.52 and a 1 year high of $27.19.
Novan Company Profile
Novan, Inc is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs).
Receive News & Ratings for Novan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novan and related companies with MarketBeat.com's FREE daily email newsletter.